Amgen reveals more details of denosumab's fracture benefit
This article was originally published in Scrip
Executive Summary
Amgen's investigational bone loss treatment denosumab more than halves osteoporosis patients' risk of new vertebral fractures, new data from a pivotal Phase III trial show.